Product Description
Tavaborole topical solution, 5% (tavaborole) is a novel, boron-based, antifungal pharmaceutical agent indicated for treatment of toenail onychomycosis due to the dermatophytes Trichophyton rubrum or Trichophyton mentagrophytes. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26583302/)
Mechanisms of Action: Protein Synthesis Inhibitor,t-RNA synthetase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Egypt | United States
Approved Indications: Onychomycosis
Known Adverse Events: Dermatitis | Erythema
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|